Identification of Ribonuclease Inhibitors for the Control of Pathogenic Bacteria.

Area of Science:

• Microbiology and Molecular Biology
• Drug Discovery and Medicinal Chemistry

Background:

• Antibiotic resistance in bacteria poses a significant global health threat, necessitating the development of novel therapeutic strategies.
• Bacterial exoribonucleases, such as polynucleotide phosphorylase (PNPase) and RNase II, are crucial for RNA metabolism and microbial survival.
• These enzymes are implicated in the virulence of various pathogens, making them attractive targets for new antibacterial drug development.

Purpose of the Study:

• To identify novel chemical compounds that inhibit the activity of essential bacterial exoribonucleases, RNase II and PNPase from Escherichia coli.
• To validate the use of virtual high-throughput screening (vHTS) coupled with in vitro assays for discovering antibacterial agents.
• To provide proof of principle for targeting these enzymes in the development of next-generation antibiotics.

Main Methods:

• Virtual high-throughput screening (vHTS) was employed to predict compounds binding to the active sites of E. coli RNase II and PNPase.
• Identified compounds underwent in vitro screening to assess their inhibitory effects on exoribonuclease activity.
• The impact of selected compounds on bacterial cell viability was evaluated.

Main Results:

• vHTS successfully identified chemical compounds with predicted binding affinity to RNase II and PNPase active sites.
• In vitro screening confirmed that several identified compounds inhibited the enzymatic activity of these exoribonucleases.
• Some validated compounds also demonstrated a reduction in bacterial cell viability, indicating potential antibacterial effects.

Conclusions:

• The study demonstrates the efficacy of using structural information of bacterial RNase II and PNPase for virtual screening.
• This approach successfully identified novel inhibitors of essential exoribonucleases, validating them as targets for antibacterial development.
• The findings support the pursuit of structure-based drug design targeting bacterial RNA processing enzymes to combat antibiotic resistance.